Volume 5.26 | Jul 4

Cord Blood News 5.26 July 4, 2013
Cord Blood News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Miniature Human Liver Grown in Mice
Transplanting tiny ‘liver buds’ constructed from human stem cells restores liver function in mice, researchers have found. The researchers make the liver buds from three types of human cells. First, they coax induced pluripotent stem cells into a cell type that expresses liver genes. Then they add endothelial cells (which line blood vessels) from umbilical cord blood, and mesenchymal stem cells, which can make bone, cartilage and fat. [Press release from Nature News discussing online prepublication in Nature] Press Release | Abstract
Live Webinar: Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells. Register Now!
PUBLICATIONS (Ranked by impact factor of the journal)
Monocytes Play an IL-12-Dependent Crucial Role in Driving Cord Blood NK Cells to Produce IFN-g in Response to Trypanosoma cruzi
Researchers compared the ability of Trypanosoma cruzi to activate cord blood and adult NK cells from healthy individuals. Twenty-four hours co-culture of cord blood mononuclear cells with T. cruzi trypomastigotes and IL-15 induced high accumulation of IFN-g transcripts and IFN-g release. [PLoS Negl Trop Dis] Full Article

Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity
Neonatal Natural Killer (NK) cells show functional impairment and expansion of a CD56 negative population of uncertain significance. NK cells were isolated from cord blood and from adult donors. NK subpopulations were identified as positive or negative for the expression of CD56 and characterized for expression of granzyme B and surface markers by multi-parameter flow cytometry. [PLoS One] Full Article

Effects of Cryopreservation on Microbial-Contaminated Cord Blood
Investigators aimed to determine whether contaminating organisms in cord blood units survive the cryopreservation, frozen storage, and subsequent thawing conditions before infusion. [Transfusion] Abstract

Successful Cord Blood Transplantation after Repeated Transfusions of Unmobilized Neutrophils in Addition to Antifungal Treatment in an Infant with Chronic Granulomatous Disease Complicated by Invasive Pulmonary Aspergillosis
A two-week-old girl developed invasive pulmonary aspergillosis, which rapidly progressed to respiratory failure. At the age of two months, she was diagnosed with p67phox-deficient chronic granulomatous disease. Rituximab was administered to reduce alloimmunization to human leukocyte antigens (HLA) after the eighth granulocyte transfusion, resulting in their absence of anti-HLA before and after cord blood transplantation (CBT). A marked improvement in her invasive pulmonary aspergillosis was achieved, although the first CBT was rejected. Complete hematopoietic recovery was obtained after the second CBT. [Transfusion] Abstract

Hematopoietic Stem Cell Transplantation with Umbilical Cord Multipotent Stromal Cell Infusion for the Treatment of Aplastic Anemia – A Single-Center Experience
Researchers observed the outcome of co-transfusion of umbilical cord multipotent stromal cells and allogeneic hematopoietic stem cells in the treatment of heavily-transfused patients with severe aplastic anemia. [Cytotherapy] Abstract

Characterization of Hepatic Markers in Human Wharton’s Jelly-Derived Mesenchymal Stem Cells
An in-depth analysis of the expression of liver-specific transcription factors and other key hepatic markers in human Wharton’s Jelly-derived mesenchymal stem cells was evaluated at both the mRNA and protein level. [Toxicol In Vitro] Abstract

Cord Blood Monocytes, Neutrophils and Lymphocytes from Preterm and Full-Term Neonates Show Multiple Aberrations in Signaling Profiles Measured Using Phospho-Specific Whole Blood Flow Cytometry
Immaturity of the immune system renders newborns susceptible to infections. The authors searched for aberrations in leukocyte signaling profiles, using phospho-specific whole blood flow cytometry, in cord blood of nine preterm (two born before 32nd gestational week) and nine full-term infants, born by caesarean section. [Scand J Immunol] Abstract

Production, Characterization, and Cytocompatibility of Porous Titanium-Based Particulate Scaffolds
Three Ti-6Al-4V materials were metal injection molded and tailored porosities were effectively achieved. After microstructural and mechanical characterization, two different primary cells of mesenchymal origin (human umbilical cord perivascular cells and human bone derived cells which revealed to be two pertinent models) as well as one cell line originated from primary osteogenic sarcoma, Saos-2, were bestowed to investigate cell-material interaction on genomic and proteome levels. [J Mater Sci Mater Med] Abstract

New StemSpan(TM) SFEM II - for optimal CD34+ cell expansion of bone marrow and cord blood cells
The Potential for Cell-Based Therapy in Perinatal Brain Injuries
Animal studies support the idea that a number of stem cells types, including cord blood and mesenchymal stem cells have a neuroprotective effect in neonatal hypoxia-ischemia. Researchers review the different types of stem cells and progenitor cells that are potential candidates for therapeutic strategies in perinatal brain injuries and summarize recent preclinical and clinical studies. [Transl Stroke Res] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Abstracts – 11th Annual International Cord Blood Symposium

New wallchart from our sponsor: Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
Gamida Cell Reports FDA Recommending Further Study of StemEx®
Gamida Cell announced that while the current single arm Phase II/III study, incorporating a historical cohort as the study control, provides evidence of activity of StemEx®, the FDA has advised Gamida Cell to conduct another trial – a Phase III, randomized, controlled clinical study. StemEx® is in development as an alternative transplantation treatment for patients with high risk leukemia and lymphoma, who could not find a family related matched bone marrow donor. [Gamida Cell] Press Release

BioBridge Global Announced as Holding Company Name for South Texas Blood & Tissue Center and Affiliates
BioBridge Global was announced as the name of the non-profit holding company that includes South Texas Blood & Tissue Center, QualTex Laboratories and GenCure. The new name reflects the organization’s mission to bridge the critical needs in the medical industry and build global partnerships that save lives, according to Board Chair Dennis Stahl and Linda Myers, CEO of BioBridge Global. [South Texas Blood & Tissue Center] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 5th International Stem Cell Meeting
October 8-9, 2013
Jerusalem, Israel

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Position – Hematopoietic Differentiation of Pluripotent Stem Cells (Center for Physiology and Pathophysiology, University of Cologne)

Postdoctoral Position – Hematopoiesis & Leukemogenesis (University of Massachusetts Medical School)

Postdoctoral Positions – Stem Cell Biology and Epigenetics (University of Wisconsin-Madison)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Postdoctoral Researcher – Basic and Translational Hemato-Oncology (Josep Carreras Leukaemia Research Institute)

Laboratory Manager – Basic and Translational Hemato-Oncology (Josep Carreras Leukaemia Research Institute)

PhD Student Position – Hematopoietic Stem Cells (Katholieke Universiteit Leuven)

Postdoctoral Researcher – Hematopoietic Stem Cells (Albert Einstein College of Medicine)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Cord Blood News: Archives | Events | Contact Us